This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office division, a major pharmaceutical distributor. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, to DLA facilities supporting the U.S. Department of Defense. The contract has a ceiling value of $2,306.20 and a period of performance through July 9, 2024. This contract is not designated as a set-aside. AmerisourceBergen also holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, to provide a broad range of pharmaceutical products and medical supplies to the Department of Defense globally. Additionally, the company holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.
Generated 10/7/24, 10:48 AM